Analysts expect BioVie Inc. to report a consensus revenue of $0.00 and an EPS loss of $0.52 for the second calendar quarter of 2026. The current stock price of approximately $1.09 trades significantly below the $5.26 average analyst price target, reflecting high volatility in the clinical-stage biotech sector.
Investors are primarily focused on upcoming topline data from the ADDRESS-LC Phase 2 trial for Long COVID, expected in late summer 2026. This follows positive Phase 2b results for the Parkinson's candidate bezisterim, which met its primary pharmacodynamic endpoints in early August. Management's commentary on Phase 3 trial designs for both Parkinson's and Alzheimer's disease will be critical for future valuation.